← 返回

基于放射组学的间皮瘤患者 TRuC-T 细胞治疗反应预测:一项初步研究

英文原题:Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.

查看英文原题

Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study.

PubMed 2025/01/29(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

基于机器学习的放射组学/Δ放射组学分析可实现对靶向胸膜肿瘤反应的预测。肿瘤特异性可重复性和平均值表明,使用肿瘤模型构建有效的患者模型需要结合多个靶向肿瘤模型。

研究思路结论见上方概要

T细胞受体融合构建体(TRuCs)作为下一代工程化T细胞疗法,前景广阔。为加速这些疗法的临床开发,改进患者选择是一条至关重要的前进路径。

我们回顾性分析了23例间皮瘤患者(85个靶肿瘤),这些患者参加了一项1/2期单臂临床试验(NCT03907852)。涉及5个影像学中心,评估设置为盲法独立中心评审(BICRs),采用双读。评估了3416个影像组学和delta-影像组学(Δradiomics)的可重复性。单变量分析评估了靶肿瘤水平与以下各项的相关性:(1)肿瘤直径反应;(2)根据定量影像生物标志物联盟的肿瘤体积反应;以及(3)根据实体肿瘤正电子发射断层扫描反应标准(PERCISTs)定义的平均标准摄取值(SUV)反应。随机森林模型预测了靶胸膜肿瘤的反应。

肿瘤解剖分布分别为胸膜55.3%、淋巴结17.6%、腹膜14.1%和软组织10.6%。放射组学/Δ放射组学的可重复性因肿瘤定位而异。放射组学比Δ放射组学更具可重复性。在单变量分析中,没有任何放射组学/Δ放射组学与任何反应标准相关。三种放射组学/Δ放射组学能够预测靶向胸膜肿瘤的反应,准确度范围为0.75至0.9。关键研究将需要250至400个肿瘤的样本量。

展开英文摘要原文

We retrospectively analyzed 23 mesothelioma patients (85 target tumors) treated in a phase 1/2 single arm clinical trial (NCT03907852). Five imaging sites were involved, the settings for the evaluations were Blinded Independent Central Reviews (BICRs) with double reads. The reproducibility of 3416 radiomics and delta-radiomics (Δradiomics) was assessed. The univariate analysis evaluated correlations at the target tumor level with (1) tumor diameter response; (2) tumor volume response, according to the Quantitative Imaging Biomarker Alliance; and (3) the mean standard uptake value (SUV) response, as defined by the positron emission tomography response criteria in solid tumors (PERCISTs). A random forest model predicted the response of the target pleural tumors.

Tumor anatomical distribution was 55.3%, 17.6%, 14.1%, and 10.6% in the pleura, lymph nodes, peritoneum, and soft tissues, respectively. Radiomics/Δradiomics reproducibility differed across tumor localizations. Radiomics were more reproducible than Δradiomics. In the univariate analysis, none of the radiomics/Δradiomics correlated with any response criteria. With an accuracy ranging from 0.75 to 0.9, three radiomics/Δradiomics were able to predict the response of target pleural tumors. Pivotal studies will require a sample size of 250 to 400 tumors.

The prediction of responding target pleural tumors can be achieved using a machine learning-based radiomics/Δradiomics analysis. Tumor-specific reproducibility and the average values indicated that using tumor models to create an effective patient model would require combining several target tumor models.

论文信息

作者
Beaumont H、Iannessi A、Thinnes A、Jacques S、Quintás-Cardama A
第一作者单位
Median Technologies, 06560 Valbonne, France.Germany
通讯作者单位
TCR2 Therapeutics, Cambridge, MA 02142, USA.United States
期刊
Cancers2025 Jan 29
原文标识
PubMed 39941830 · DOI 10.3390/cancers17030463